Last reviewed · How we verify

NCT03063112: RF

Radiofrequency and Chemical Neurolysis of Thoracic Splanchnic Nerve for Abdominal Cancer Pain

Status unknown NA Last updated 28 February 2017
What this trial tests

NA trial testing Radiofrequency generator device in Abdominal Cancer in 79 participants. Status unknown.

Timeline
1 October 2016
Primary endpoint
10 April 2017
1 May 2017

Quick facts

Lead sponsorSouth Egypt Cancer Institute
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposesupportive care
Enrollment79
Start date1 October 2016
Primary completion10 April 2017
Estimated completion1 May 2017
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

South Egypt Cancer Institute

Who can join

Adults 18 to 70, any sex, with Abdominal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study compares between the efficacy, safety and impact on the quality of life of radiofrequency thermocoagulation and chemical neurolysis of bilateral thoracic splanchnic nerves in the management of refractory pain which developed in patients suffering from upper abdominal cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Abdominal Cancer

Currently open trials in the same condition.

Other South Egypt Cancer Institute trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03063112.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing